<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">20150394</PMID>
<DateCompleted>
<Year>2010</Year>
<Month>07</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-0970</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>16</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2010</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Multiple sclerosis (Houndmills, Basingstoke, England)</Title>
<ISOAbbreviation>Mult. Scler.</ISOAbbreviation>
</Journal>
<ArticleTitle>Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters.</ArticleTitle>
<Pagination>
<MedlinePgn>387-97</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1352458509359722</ELocationID>
<Abstract>
<AbstractText>Lipoic acid is a natural antioxidant available as an oral supplement from a number of different manufacturers. Lipoic acid administered subcutaneously is an effective therapy for murine experimental autoimmune encephalomyelitis, a model of multiple sclerosis. The aim of this study was to compare serum lipoic acid levels with oral dosing in patients with multiple sclerosis with serum levels in mice receiving subcutaneous doses of lipoic acid. We performed serum pharmacokinetic studies in patients with multiple sclerosis after a single oral dose of 1200 mg lipoic acid. Patients received one of the three different racemic formulations randomly: tablet (Formulation A) and capsules (Formulations B and C). Mice pharmacokinetic studies were performed with three different subcutaneous doses (20, 50 and 100 mg/kg racemic lipoic acid). The pharmacokinetic parameters included Maximum Serum Concentrations (C(max) in microg/ml) and area under the curve (0-infinity) (AUC ( 0-infinity) in microg*min/ml). We found mean C(max) and AUC (0-infinity) in patients with multiple sclerosis as follows: group A (N = 7) 3.8 +/- 2.6 and 443.1 +/- 283.9; group B (N = 8) 9.9 +/- 4.5 and 745.2 +/- 308.7 and group C (N = 8) 10.3 +/- 3.8 and 848.8 +/- 360.5, respectively. Mean C(max) and AUC (0-infinity) in the mice were: 100 mg/kg lipoic acid: 30.9 +/- 2.9 and 998 +/- 245; 50 mg/kg lipoic acid: 7.6 +/- 1.4 and 223 +/- 20; 20 mg/kg lipoic acid: 2.7 +/- 0.7 and 119 +/- 33. We conclude that patients taking 1200 mg of lipoic acid from two of the three oral formulations achieved serum C(max) and AUC levels comparable to that observed in mice receiving 50 mg/kg subcutaneous dose of lipoic acid, which is a highly therapeutic dose in experimental autoimmune encephalomyelitis. A dose of 1200 mg oral lipoic acid can achieve therapeutic serum levels in patients with multiple sclerosis.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Yadav</LastName>
<ForeName>Vijayshree</ForeName>
<Initials>V</Initials>
<AffiliationInfo>
<Affiliation>Department of Neurology, Oregon Health &amp; Science University, Portland, OR 97239, USA. yadavv@ohsu.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Marracci</LastName>
<ForeName>Gail H</ForeName>
<Initials>GH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Munar</LastName>
<ForeName>Myrna Y</ForeName>
<Initials>MY</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cherala</LastName>
<ForeName>Ganesh</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Stuber</LastName>
<ForeName>Lauren E</ForeName>
<Initials>LE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alvarez</LastName>
<ForeName>Lilia</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shinto</LastName>
<ForeName>Lynne</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koop</LastName>
<ForeName>Dennis R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bourdette</LastName>
<ForeName>Dennis N</ForeName>
<Initials>DN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K23 AT003258</GrantID>
<Acronym>AT</Acronym>
<Agency>NCCIH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>UL1 RR024140</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2010</Year>
<Month>02</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Mult Scler</MedlineTA>
<NlmUniqueID>9509185</NlmUniqueID>
<ISSNLinking>1352-4585</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002214">Capsules</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013607">Tablets</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>73Y7P0K73Y</RegistryNumber>
<NameOfSubstance UI="D008063">Thioctic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000975">Antioxidants</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019540">Area Under Curve</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001682">Biological Availability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002214">Capsules</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D019587">Dietary Supplements</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004681">Encephalomyelitis, Autoimmune, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006207">Half-Life</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007155">Immunologic Factors</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007279">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008657">Metabolic Clearance Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009103">Multiple Sclerosis</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013607">Tablets</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008063">Thioctic Acid</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000493">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014018">Tissue Distribution</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2010</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2010</Year>
<Month>2</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2010</Year>
<Month>7</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">20150394</ArticleId>
<ArticleId IdType="pii">1352458509359722</ArticleId>
<ArticleId IdType="doi">10.1177/1352458509359722</ArticleId>
<ArticleId IdType="pmc">PMC3489916</ArticleId>
<ArticleId IdType="mid">NIHMS398717</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Neuroimmunol. 2008 Aug 13;199(1-2):46-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18562016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Clin Endocrinol Diabetes. 1999;107(7):421-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10595592</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Altern Complement Med. 2007 Jun;13(5):577-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17604563</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuroimmunol. 2002 Oct;131(1-2):104-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12458042</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Biochem Biophys. 1974 Feb;160(2):514-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4598618</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep 25;824(1-2):249-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16112626</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neuroimmunol. 2004 Mar;148(1-2):146-53</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14975595</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2008 Jun 21;371(9630):2085-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18572078</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Clin Pharmacol Ther. 1998 Dec;36(12):625-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9876998</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Gerontol Geriatr. 2001 Jun;32(3):275-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11395173</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Oral Pathol Med. 2009 Mar;38(3):254-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19175713</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabet Med. 1999 Dec;16(12):1040-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10656234</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Biol Med. 1997;22(1-2):359-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8958163</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Neurol. 2001 Jul;50(1):121-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11456302</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2006 Aug 15;177(4):2630-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16888025</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17548489</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Free Radic Res. 1999 Sep;31(3):171-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10499773</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Soc Trans. 2006 Aug;34(Pt 4):476-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16856837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Metab Dispos. 2001 Jun;29(6):855-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11353754</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Care. 1999 Aug;22(8):1296-301</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10480774</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nutr Rev. 2008 Nov;66(11):646-57</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19019027</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Renal Physiol. 2008 Jan;294(1):F272-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18032550</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurosci Res. 2004 Nov 1;78(3):362-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15389837</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Headache. 2007 Jan;47(1):52-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17355494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1992 Mar 5;356(6364):63-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1538783</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Clin Pharmacol. 1996;50(6):513-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8858282</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurology. 2009 Jan 6;72(1):73-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19122034</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Kidney Int. 2006 Nov;70(9):1636-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16955108</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Gen Pharmacol. 1997 Sep;29(3):315-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9378235</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arzneimittelforschung. 1995 Mar;45(3):293-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7741788</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neural Transm Suppl. 2007;(72):189-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17982894</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs. 2008;68(17):2445-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19016573</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2007 Mar 2;354(1):259-64</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17210133</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2008 Oct 25;372(9648):1463-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18970976</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Care. 1997 Mar;20(3):369-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9051389</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mult Scler. 2005 Apr;11(2):159-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15794388</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Pain. 2009 May;13(5):492-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18675569</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18764723</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2005;(1):CD002779</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15674897</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurology. 1983 Nov;33(11):1444-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6685237</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Pharmacol. 1996 Feb 9;51(3):233-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8573188</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2003 Nov;43(11):1257-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14551180</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Oral Rehabil. 2009 Jan;36(1):52-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18976257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Care. 2003 Mar;26(3):770-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12610036</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2000 Sep 28;343(13):938-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11006371</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetologia. 1995 Dec;38(12):1425-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8786016</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurology. 1999 Aug 11;53(3):466-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10449105</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Acta Neurol Scand Suppl. 2008;188:12-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18439216</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2005 Mar;45(3):313-28</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15703366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>